series-a
Stage
2021
Founded
4
Investors
About
Glyphic Biotechnologies develops a de novo high-throughput proteome sequencing technology called Protein Sequencing by Expansion (ProSE™), enabling accurate single molecule discrimination of all 20 amino acids and post-translational modifications.
Explore Glyphic Biotechnologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.